University of Kentucky Alzheimer's Disease Research Center

肯塔基大学阿尔茨海默病研究中心

• 批准号: 10261961
• 负责人: LINDA J VAN ELDIK
• 金额: $ 300.99万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10261961
• 关键词: Address; African American; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Autopsy; Awareness; Basic Science; Biological; Biological Markers; Biometry; Brain; Caring; Cessation of life; Clinical; Clinical Research; Clinical Trials; Cognitive; Cognitive aging; Collaborations; Collection; Communities; Community Outreach; Dementia; Development; Disease; Education; Education and Outreach; Elderly; Ensure; Environment; Etiology; Family; Goals; Health Personnel; Heterogeneity; Impaired cognition; Impairment; Individual; Infrastructure; Kentucky; Knowledge; Longitudinal cohort; Mission; NCI Scholars Program; Neurodegenerative Disorders; Outcome; Pathogenicity; Pathology; Recommendation; Research; Research Personnel; Research Project Grants; Resources; Risk; Training; Translating; Translational Research; United States; United States National Institutes of Health; Universities; aging brain; beneficiary; central database; clinical practice; cognitive development; cohesion; cohort; collaborative environment; community partnership; comorbidity; data management; driving force; education research; experience; innovation; neuropathology; next generation; normal aging; novel therapeutics; outreach; pre-clinical; programs; recruit; research study; statistics; success; volunteer

Project Summary/Abstract: Overall The University of Kentucky Alzheimer’s Disease Research Center (UK-ADRC) is an experienced and collaborative center that has facilitated pioneering research in AD and related dementias (ADRD) since its inception in 1985. Our principal mission is to serve as the focal point for all AD-related activities at UK and this region of the United States, by providing an environment and core resources that catalyze innovative research, outreach, education, and clinical programs. Our signature resources include: 1) a cognitively normal group of ~500 subjects followed longitudinally, together with ~300 additional subjects who transitioned to MCI or dementia, and all committed to brain autopsy upon death; 2) a strong autopsy program with clinical- neuropathological correlations and short postmortem interval research material; 3) a maturing program studying the early preclinical biological emergence of mixed pathologies and how they contribute to late life dementia states, with an increasing focus on antemortem biomarker collection; 4) an integrated centralized database and innovative biostatistical expertise to characterize clinical and biological transitions; 5) a successful and close partnership with the African-American community and increased participation of underrepresented individuals in our longitudinal cohort and ADRC-affiliated research studies and clinical trials; and 6) a rich, interdisciplinary training environment that provides multi-faceted educational opportunities for researchers, healthcare providers, and our community partners. The overarching theme of the UK-ADRC is: Transitions from Normal to Late-Life Multi-Etiology Dementia. Our well-characterized, longitudinal cohort and historically strong neuropathology program focused on normal aging, preclinical disease states and early cognitive transitions have been central to our success in defining early pathogenic mechanisms underlying the transitions from normal cognitive aging to impairment. In addition, these efforts have been a driving force in our recognition of the heterogeneity and multiple pathologies that characterize late-life dementia. The UK-ADRC will continue to leverage our strengths to enhance our impact and “Centerness” by our focus on this overarching theme, and the pursuit of four overall specific aims. Aim 1. Facilitate and enhance basic, translational and clinical research in AD and related dementias. Aim 2. Provide the necessary resources and interactive environment to support and create new opportunities for innovative research. Aim 3. Maintain and grow educational opportunities and community partnerships to promote awareness, increase participation in research, and provide an innovative and interdisciplinary training environment. Aim 4. Contribute to the national efforts and collaborative activities with other centers, programs and groups to advance AD/ADRD research, education, and care.

项目摘要/摘要：总体 肯塔基大学阿尔茨海默氏病研究中心（UK-ADRC）是一种经验， 合作中心已经准备了AD和相关痴呆症（ADRD）的开拓性研究 1985年成立。我们的主要任务是作为英国所有与广告相关活动的焦点，这 美国地区，通过提供催化创新研究的环境和核心资源， 外展，教育和临床计划。我们的签名资源包括：1）认知正常的组 〜500名受试者纵向跟随，以及〜300名过渡到MCI或的受试者 痴呆症，所有人都致力于死亡时进行大脑尸检； 2）临床的强大尸检计划 - 神经病理学相关性和术后间隔研究材料短； 3）成熟计划 研究混合病理的早期临床前生物学出现及其如何为晚期贡献 痴呆症表明，越来越关注触角生物标志物的收集； 4）集成集中的 数据库和创新的生物统计专业知识，以表征临床和生物学转变； 5）a 与非洲裔美国人社区的成功和密切合作伙伴关系，并增加了参与 在我们的纵向队列和ADRC附属研究研究和临床试验中，代表性不足的个体； 6）一个丰富的跨学科培训环境，为多方面的教育机会提供 研究人员，医疗保健提供者和我们的社区合作伙伴。英国-ADRC的总体主题是： 从正常生命到多性痴呆症的过渡。我们的纵向纵向队列 历史上强烈的神经病理学计划着重于正常衰老，临床前疾病状态和早期 认知转变是我们在定义早期致病机制方面成功的核心 从正常认知衰老到损害的过渡。此外，这些努力一直是我们的驱动力 识别表征晚年痴呆症的异质性和多种病理。英国-Adrc 通过对此，将继续利用我们的优势来增强我们的影响和“中心” 总体主题，并追求四个总体特定目标。 目标1。促进并增强AD和相关痴呆症的基础，翻译和临床研究。 目标2。提供必要的资源和互动环境来支持和创造新的机会 用于创新研究。 目标3。维持和发展教育机会和社区伙伴关系，以促进意识， 增加参与研究，并提供创新的跨学科培训环境。 目标4。为与其他中心，计划和团体的国家努力和合作活动做出贡献 提前广告/ADRD研究，教育和护理。